aap successfully places a 5.7% capital increase from authorised capital at EUR 1.34, excluding subscription rights

• The cash inflow will strengthen investments in the approval of innovative antibacterial implant technology

aap Implantate AG ("aap" or "Company") successfully completed the 5.7% capital increase announced on 4 December 2025, excluding subscription rights, at a placement price of EUR 1.34. This will provide the Company with cash proceeds of EUR 1,056,121.00. This cash inflow will strengthen investments in the approval costs for the innovative antibacterial implant technology. The capital increase was oversubscribed.

----------------------------------------------------------------

aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock exchanges –

About aap Implantate AG

aap Implantate AG is a global medical technology company based in Berlin, Germany. The company develops, manufactures and markets products for traumatology. In addition to the innovative LOQTEQ® anatomical plate system, its IP-protected portfolio includes a wide range of screw plates. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects, such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. aap Implantate AG sells its products in Germany directly to hospitals, purchasing groups and hospital networks, while at the international level it primarily uses a broad network of distributors in around 31 countries. In the USA, the company relies on a sales strategy via distribution agents through its subsidiary aap Implants Inc. The shares of aap Implantate AG are listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.

The figures presented in this press release may contain technical rounding differences that do not affect the overall statement.

Forward-looking statements

This press release may contain forward-looking statements based on the current expectations, assumptions and forecasts of the Management Board and the information currently available to it. Forward-looking statements are not guarantees of future developments and results. Various known and unknown risks, uncertainties and other factors could lead to the actual results, financial position, development or performance of the company differing materially from the estimates given here. These factors also include those described by aap in published reports. Forward-looking statements are therefore only valid on the day they are made. We undertake no obligation to update the forward-looking statements made in this announcement or to adapt them to future events or developments.

If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo, Chairman of the Executive Board/CEO, Lorenzweg 5; 12099 Berlin

Tel.: +49 (0)30 75019 – 170 ; Fax : +49 (0)30 75019 – 290 ; Email : r.digirolamo@aap.de